Laboratory of Plant Physiology, Wageningen University, Wageningen, The Netherlands.
PLoS One. 2010 Dec 3;5(12):e14222. doi: 10.1371/journal.pone.0014222.
Production of pharmaceuticals in plants provides an alternative for chemical synthesis, fermentation or natural sources. Nicotiana benthamiana is deployed at commercial scale for production of therapeutic proteins. Here the potential of this plant is explored for rapid production of precursors of artemisinin, a sesquiterpenoid compound that is used for malaria treatment.
METHODOLOGY/PRINCIPAL FINDINGS: Biosynthetic genes leading to artemisinic acid, a precursor of artemisinin, were combined and expressed in N. benthamiana by agro-infiltration. The first committed precursor of artemisinin, amorpha-4,11-diene, was produced upon infiltration of a construct containing amorpha-4,11-diene synthase, accompanied by 3-hydroxy-3-methylglutaryl-CoA reductase and farnesyl diphosphate synthase. Amorpha-4,11-diene was detected both in extracts and in the headspace of the N. benthamiana leaves. When the amorphadiene oxidase CYP71AV1 was co-infiltrated with the amorphadiene-synthesizing construct, the amorpha-4,11-diene levels strongly decreased, suggesting it was oxidized. Surprisingly, no anticipated oxidation products, such as artemisinic acid, were detected upon GC-MS analysis. However, analysis of leaf extracts with a non-targeted metabolomics approach, using LC-QTOF-MS, revealed the presence of another compound, which was identified as artemisinic acid-12-β-diglucoside. This compound accumulated to 39.5 mg x kg(-1) fwt. Apparently the product of the heterologous pathway that was introduced, artemisinic acid, is further metabolized efficiently by glycosyl transferases that are endogenous to N. benthamiana.
CONCLUSION/SIGNIFICANCE: This work shows that agroinfiltration of N. bentamiana can be used as a model to study the production of sesquiterpenoid pharmaceutical compounds. The interaction between the ectopically introduced pathway and the endogenous metabolism of the plant is discussed.
在植物中生产药物为化学合成、发酵或天然来源提供了替代方案。本氏烟被应用于商业规模生产治疗蛋白。在此,探索了该植物在快速生产青蒿素前体方面的潜力,青蒿素是一种倍半萜类化合物,用于治疗疟疾。
方法/主要发现:通过农杆菌浸润,将导致青蒿酸(青蒿素的前体)产生的生物合成基因组合并在本氏烟中表达。当含有法呢基二磷酸合酶和 3-羟基-3-甲基戊二酰基辅酶 A 还原酶的构建体浸润时,产生了青蒿素的第一个关键前体阿莫法-4,11-二烯。阿莫法-4,11-二烯既存在于提取物中,也存在于本氏烟叶片的顶空部分。当与合成阿莫法-4,11-二烯的构建体共浸润时,CYP71AV1 氧化酶强烈降低了阿莫法-4,11-二烯的水平,表明其被氧化。令人惊讶的是,GC-MS 分析并未检测到预期的氧化产物,如青蒿酸。然而,使用 LC-QTOF-MS 进行非靶向代谢组学分析表明,在叶提取物中存在另一种化合物,被鉴定为青蒿酸-12-β-二葡萄糖苷。该化合物积累到 39.5mg x kg(-1) fwt。显然,引入的异源途径的产物青蒿酸被本氏烟内源性的糖基转移酶进一步有效地代谢。
结论/意义:这项工作表明,农杆菌浸润本氏烟可以作为研究倍半萜类药物化合物生产的模型。讨论了外源途径与植物内源性代谢之间的相互作用。